Concepedia

Reference Product Availability

Reference Product Availability is a scholarly contribution representing a methodological framework within the domain of drug development and regulatory science that specifies the conditions under which an approved reference listed drug remains accessible and suitable for use in bioequivalence or comparative clinical studies.

25

Publications

946

Citations

117

Authors

57

Institutions

Publications per year

2017–2026

12

Parents

Publications

25

An overview of the Earth Observing System MODIS instrument and associated data systems performance

V. V. Salomonson, William L. Barnes, Jun Xiong et al. · 2003 · 188 citations

, , +13

Approval of the first biosimilar antibodies in Europe

Alain Beck, Janice M. Reichert · mAbs · 2013 · 124 citations · Full text

, , +16

Lead-Free Hunting Rifle Ammunition: Product Availability, Price, Effectiveness, and Role in Global Wildlife Conservation

Vernon G. Thomas · AMBIO · 2013 · 75 citations · Full text

, , +11

The availability of references and the sponsorship of original research cited in pharmaceutical advertisements

Richelle J. Cooper · Canadian Medical Association Journal · 2005 · 71 citations · Full text

, , +15

Streamlined approval of biosimilars: moving on from the confirmatory efficacy trial

Marie-Christine Bielsky, Anne Cook, Andrea Wallington et al. · Drug Discovery Today · 2020 · 52 citations

, , +17

1–5 of 25

Authors

117

  1. EG
    Eileen G. Abels

    University of Maryland, College Park, United States

    1 publications · 14 citations

    1

    h-index

  2. CY
    Carolyn Y. Muller

    University of New Mexico, United States

    1 publications · 28 citations

    1

    h-index

  3. PS
    Paula Silverman

    Case Western Reserve University, United States

    1 publications · 14 citations

    1

    h-index

  4. JA
    John A. Dumot

    Cleveland Clinic, United States

    1 publications · 14 citations

    1

    h-index

  5. SH
    Shahzad Hussain

    National Institute of Health, Pakistan

    1 publications · 28 citations

    1

    h-index

1–5 of 117

Institutions

57

  1. Amgen (United States)

    Thousand Oaks, United States

    2 h-index

    4 publications

    79 citations

  2. Collaborative Research Group

    Sydney, Australia

    1 h-index

    3 publications

    30 citations

  3. University of Maiduguri

    Maiduguri, Nigeria

    1 h-index

    1 publications

    16 citations

  4. Institute for Safe Medication Practices

    Horsham, United States

    1 h-index

    1 publications

    44 citations

  5. Indian Institute of Technology Delhi

    New Delhi, India

    1 h-index

    2 publications

    28 citations

  6. Michigan Medicine

    Ann Arbor, United States

    1 h-index

    1 publications

    34 citations

  7. Procter & Gamble (Germany)

    Schwalbach am Taunus, Germany

    1 h-index

    2 publications

    26 citations

  8. Procter & Gamble (United States)

    Cincinnati, United States

    1 h-index

    1 publications

    13 citations

1–8 of 57

Venues

  1. Future Oncology

    2 publications · 25 citations

    2

    h-index

  2. American Journal of Health-System Pharmacy

    AJHP · 1 publications · 14 citations

    1

    h-index

  3. Cutaneous and Ocular Toxicology

    1 publications · 13 citations

    1

    h-index

  4. 1

    h-index

  5. Revista Brasileira de Farmacognosia

    1 publications · 51 citations

    1

    h-index

1–5